Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TG Therapeutics Inc
TGTX | US
40.11
USD3.47
9.47%
TGTX | US
About TG Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
40.11
Open
38.65
High
41.34
Low
37.96
TG Therapeutics Inc. a commercial stage biopharmaceutical company focuses on the acquisition development and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome relapsing-remitting disease and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801 a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys as well as collaboration agreement with Checkpoint Therapeutics Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics Inc. was incorporated in 1993 and is based in Morrisville North Carolina.
View LessTGTX | US
Risk
71.8
Sharpe
0.15
Luna's Score
51/100
Recommendation
Hold
Luna says (TGTX | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Strong Revenue Growth (> 10%)
What's not Working
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
55.9%1 month
71.8%3 months
56.0%6 months
48.1%Returns
Fundamental Ratios
PE
34.28
Fwd. PE
40.65
Price to book
20.87
Debt to equity
0.63
Debt to assets
0.28
Ent. to EBITDA
33.18
Ent. to rev.
10.39
PEG
-
Other Fundamentals
EBITDA
102.00M
MarketCap
6.21B
MarketCap(USD)
6.21B
Div. yield
-
Op. margin
12.00
Erngs. growth
-
Rev. growth
357.00
Ret. on equity
87.78
Short ratio
7.32
Short perc.
24.56
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
4.87
Range1M
10.87
Range3M
17.89
Volumes: Market Activity
Rel. volume
1.68
Price X volume
145.28M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 33.18 | - | Expensive |
| Ent. to Revenue | 10.39 | - | Cheaper |
| PE Ratio | 34.28 | 41.03 | Par |
| Price to Book | 20.87 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 56.03 | - | Lower Risk |
| Debt to Equity | 0.63 | -1.23 | Expensive |
| Debt to Assets | 0.28 | 0.25 | Par |
| Market Cap | 6.21B | - | Market Leader |
